.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
QuintilesIMS
Baxter
Moodys
AstraZeneca
Johnson and Johnson
UBS
Chinese Patent Office
Merck
Farmers Insurance

Generated: September 20, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 5,965,590 protect, and when does it expire?


Patent ► Subscribe protects ALINIA and is included in one NDA.

This patent has one hundred and twenty-one patent family members in forty-two countries.

Summary for Patent: ► Subscribe

Title: Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide
Abstract:Methods for treatment of Cryptosporidium parvum, Isospora belli, Enterocytzoon bieneusi, Encephalitozoon intestinalis, Mycobacterium tuberculosis, Mycobacterium avium intracellulare, Pneumocystis carinii, and Toxoplasma gondii, the methods comprising the administration of a pharmaceutical composition containing as active agent at least one compound selected the group consisting of a compound of formula I: ##STR1## and a compound of formula II: ##STR2##
Inventor(s): Rossignol; Jean-Fran.cedilla.ois (Clearwater, FL)
Assignee:
Application Number:08/887,809
Patent Claim Types:
see list of patent claims
Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Romark
ALINIA
nitazoxanide
FOR SUSPENSION;ORAL021498-001Nov 22, 2002RXYesYes► Subscribe► Subscribe METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED MAMMAL
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: ► Subscribe

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,387,598 Composition and galenic formulation suitable for combatting affections of the lower abdomen► Subscribe
5,886,013 Antiviral composition► Subscribe
5,859,038 Method for treatment of helicobacter pylori infections► Subscribe
5,856,348 Method for treatment of trematodes with pharmaceutical compositions of tizoxanide and nitazoxanide► Subscribe
6,051,576 Means to achieve sustained release of synergistic drugs by conjugation► Subscribe
6,117,894 Acid stabilized pharmaceutical compositions of tizoxanide and nitazoxanide► Subscribe
5,578,621 Benzamide derivatives► Subscribe
6,020,353 2-(hydroxy)-N-(5-nitro-2-thiazolyl) benzamide► Subscribe
5,968,961 Pharmaceutical compositions of tizoxanide and nitazoxanide► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Hong Kong1025907► Subscribe
Canada2182228► Subscribe
Canada2187110► Subscribe
Canada2288003► Subscribe
Canada2418634► Subscribe
China1145621► Subscribe
China1072654► Subscribe
China1255060► Subscribe
China1158074► Subscribe
China1552322► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
US Army
Farmers Insurance
Johnson and Johnson
QuintilesIMS
Express Scripts
Fish and Richardson
Teva
Argus Health
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot